$BLNC
Balance Labs, Inc. Stock $blnc

$blnc Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223027864 Filed on August 11, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue			$67.50K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$34.48K	$41.17K	$79.03K
YoY Change	38.75%	-47.91%	-17.36%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization			$0.00
YoY Change			-100.0%
% of Gross Profit
Operating Expenses	$34.48K	$41.17K	$79.03K
YoY Change	38.73%	-47.91%	-17.36%
Operating Profit	-$34.48K	-$41.17K	-$11.53K
YoY Change	-180.85%	256.98%	-87.94%
Interest Expense	$57.51K	$56.91K	$58.62K
YoY Change	0.0%	-2.91%	4.75%
% of Operating Profit
Other Income/Expense, Net	-$34.26K	-$55.58K	-$195.9K
YoY Change	-81.51%	-71.63%	118.74%
Pretax Income	-$68.74K	-$96.75K	-$207.4K
YoY Change	-51.79%	-53.36%	12.01%
Income Tax
% Of Pretax Income
Net Earnings	-$68.74K	-$96.75K	-$207.4K
YoY Change	-51.79%	-53.36%	13.68%
Net Earnings / Revenue			-307.3%
Basic Earnings Per Share	$0.00	$0.00	-$0.01
Diluted Earnings Per Share	$0.00	$0.00	-$9.570K
COMMON SHARES
Basic Shares Outstanding	21.67M shares	21.67M shares	21.67M shares
Diluted Shares Outstanding	21.67M shares	21.67M shares	21.67M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$324.3K	$337.9K	$546.6K
YoY Change	-37.06%	-38.2%	398.85%
Cash & Equivalents	$145.6K	$182.4K	$227.8K
Short-Term Investments	$178.7K	$155.5K	$318.9K
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables			$45.00K
Other Receivables	$0.00	$0.00	$159.4K
Total Short-Term Assets	$324.3K	$337.9K	$432.2K
YoY Change	3.22%	-21.82%	107.47%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$338.9K
YoY Change
Total Long-Term Assets	$0.00	$0.00	$338.9K
YoY Change	-100.0%	-100.0%	-73.04%
TOTAL ASSETS
Total Short-Term Assets	$324.3K	$337.9K	$432.2K
Total Long-Term Assets	$0.00	$0.00	$338.9K
Total Assets	$324.3K	$337.9K	$771.0K
YoY Change	-42.06%	-56.18%	-47.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.271M	$2.219M	$911.7K
YoY Change	149.12%	143.38%	15.16%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$1.699M	$1.699M	$1.699M
YoY Change	0.0%	0.0%	-5.91%
Long-Term Debt Due	$280.0K	$280.0K	$280.0K
YoY Change	0.0%	0.0%	2.55%
Total Short-Term Liabilities	$4.250M	$4.197M	$4.119M
YoY Change	5.0%	1.9%	4.17%
LONG-TERM LIABILITIES
Long-Term Debt	$488.7K	$485.8K	$474.5K
YoY Change	2.38%	2.39%	2.45%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$488.7K	$485.8K	$474.5K
YoY Change	2.38%	2.39%	2.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.250M	$4.197M	$4.119M
Total Long-Term Liabilities	$488.7K	$485.8K	$474.5K
Total Liabilities	$4.738M	$4.683M	$4.593M
YoY Change	4.72%	1.95%	5.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.226M	-$5.158M	-$4.635M
YoY Change	9.4%	11.28%
Common Stock	$2.167K	$2.167K	$2.167K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.414M	-$4.345M	-$3.822M
YoY Change
Total Liabilities & Shareholders Equity	$324.3K	$337.9K	$771.0K
YoY Change	-42.06%	-56.18%	-47.38%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$68.74K	-$96.75K	-$207.4K
YoY Change	-51.79%	-53.36%	13.68%
Depreciation, Depletion And Amortization			$0.00
YoY Change			-100.0%
Cash From Operating Activities	-$36.78K	-$38.66K	$13.87K
YoY Change	-172.12%	-378.73%	-124.1%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities			$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-36.78K	-38.66K	13.87K
Cash From Investing Activities			0.000
Cash From Financing Activities			0.000
Net Change In Cash	-36.78K	-38.66K	13.87K
YoY Change	-187.63%	-378.73%	-86.39%
FREE CASH FLOW
Cash From Operating Activities	-$36.78K	-$38.66K	$13.87K
Capital Expenditures			$0.00
Free Cash Flow			$13.87K
YoY Change			-128.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001632121
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2023Q2	BLNC	Selling General And Administrative Expenses Related And Nonrelated Party SellingGeneralAndAdministrativeExpensesRelatedAndNonrelatedParty		usd
	BLNC	Selling General And Administrative Expenses Related And Nonrelated Party SellingGeneralAndAdministrativeExpensesRelatedAndNonrelatedParty		usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		usd
CY2022Q2	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		usd
CY2023Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023Q2	BLNC	Accreted Interest Income And Interest Income On Note Receivable AccretedInterestIncomeAndInterestIncomeOnNoteReceivable		usd
	BLNC	Accreted Interest Income And Interest Income On Note Receivable AccretedInterestIncomeAndInterestIncomeOnNoteReceivable		usd
	BLNC	Accreted Interest On Note Receivable AccretedInterestOnNoteReceivable		usd
	BLNC	Equity Method Investment Summarized Financial Information Net Loss EquityMethodInvestmentSummarizedFinancialInformationNetLoss		usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet		usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
	BLNC	Increase Decrease In Accumulated Income Losses Of Unconsolidated Investees In Excess Of Investment IncreaseDecreaseInAccumulatedIncomeLossesOfUnconsolidatedInvesteesInExcessOfInvestment		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	BLNC	Investment At Fair Value Received From Issuance Of Note Receivable InvestmentAtFairValueReceivedFromIssuanceOfNoteReceivable		usd
	BLNC	Investment At Fair Value Received From Issuance Of Note Receivable InvestmentAtFairValueReceivedFromIssuanceOfNoteReceivable		usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
	us-gaap	Depreciation Depreciation		usd
	us-gaap	Depreciation Depreciation		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-202959
	dei	Entity Registrant Name EntityRegistrantName	BALANCE LABS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1146785
	dei	Entity Address Address Line1 EntityAddressAddressLine1	407 Lincoln Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 701
	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami Beach
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33139
	dei	City Area Code CityAreaCode	(305)
	dei	Local Phone Number LocalPhoneNumber	907-7600
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21674000	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	182400	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	235311	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	45000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	155452	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	148808	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	337852	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	429119	usd
CY2023Q2	us-gaap	Assets Assets	337852	usd
CY2022Q4	us-gaap	Assets Assets	429119	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1307113	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1220017	usd
CY2023Q2	BLNC	Accounts Payable Related Party Current AccountsPayableRelatedPartyCurrent	911659	usd
CY2022Q4	BLNC	Accounts Payable Related Party Current AccountsPayableRelatedPartyCurrent	911659	usd
CY2023Q2	BLNC	Due To Related Parties Current Exclude Notes Payable Related Parties Classified DueToRelatedPartiesCurrentExcludeNotesPayableRelatedPartiesClassified	1673558	usd
CY2022Q4	BLNC	Due To Related Parties Current Exclude Notes Payable Related Parties Classified DueToRelatedPartiesCurrentExcludeNotesPayableRelatedPartiesClassified	1673558	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	25000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	25000	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	usd
CY2023Q2	BLNC	Due To Related Party Current DueToRelatedPartyCurrent	173192	usd
CY2022Q4	BLNC	Due To Related Party Current DueToRelatedPartyCurrent	173192	usd
CY2023Q2	BLNC	Notes Payable Unamortized Discount Current NotesPayableUnamortizedDiscountCurrent	0	usd
CY2022Q4	BLNC	Notes Payable Unamortized Discount Current NotesPayableUnamortizedDiscountCurrent	0	usd
CY2023Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	106850	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	106850	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4197372	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4110276	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	14175	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	19845	usd
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	485825	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	480155	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	485825	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	480155	usd
CY2023Q2	us-gaap	Liabilities Liabilities	4683197	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4590431	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21674000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21674000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21674000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21674000	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	2167	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2167	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	810048	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	810048	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5157560	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4973527	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4345345	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4161312	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	337852	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	429119	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	67500	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	135000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7725	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7256	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11531	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11295	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	20193	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	31248	usd
	us-gaap	Professional Fees ProfessionalFees	38975	usd
	us-gaap	Professional Fees ProfessionalFees	75460	usd
CY2023Q2	us-gaap	Salaries And Wages SalariesAndWages	13252	usd
CY2022Q2	us-gaap	Salaries And Wages SalariesAndWages	10529	usd
	us-gaap	Salaries And Wages SalariesAndWages	26941	usd
	us-gaap	Salaries And Wages SalariesAndWages	33821	usd
CY2022Q2	BLNC	Selling General And Administrative Expenses Related And Nonrelated Party SellingGeneralAndAdministrativeExpensesRelatedAndNonrelatedParty	30000	usd
	BLNC	Selling General And Administrative Expenses Related And Nonrelated Party SellingGeneralAndAdministrativeExpensesRelatedAndNonrelatedParty	60000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	41170	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	79033	usd
	us-gaap	Operating Expenses OperatingExpenses	77447	usd
	us-gaap	Operating Expenses OperatingExpenses	180576	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-41170	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11533	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-77447	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-45576	usd
CY2023Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	1329	usd
CY2022Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-99649	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	6644	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-231184	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	287	usd
CY2022Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-41102	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-47256	usd
CY2022Q2	BLNC	Accreted Interest Income And Interest Income On Note Receivable AccretedInterestIncomeAndInterestIncomeOnNoteReceivable	3473	usd
	BLNC	Accreted Interest Income And Interest Income On Note Receivable AccretedInterestIncomeAndInterestIncomeOnNoteReceivable	10997	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	56912	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	58616	usd
	us-gaap	Interest Expense InterestExpense	113230	usd
	us-gaap	Interest Expense InterestExpense	116657	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-55583	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-195894	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-106586	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-383813	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-96753	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-207427	usd
	us-gaap	Net Income Loss NetIncomeLoss	-184033	usd
	us-gaap	Net Income Loss NetIncomeLoss	-429389	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21674000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21674000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21674000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21674000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21674000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21674000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21674000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21674000	shares
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4248592	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-96753	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4345345	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4161312	usd
	us-gaap	Net Income Loss NetIncomeLoss	-184033	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4345345	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3614923	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-207427	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3822350	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3392962	usd
	us-gaap	Net Income Loss NetIncomeLoss	-429389	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3822350	usd
	us-gaap	Net Income Loss NetIncomeLoss	-184033	usd
	us-gaap	Net Income Loss NetIncomeLoss	-429389	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5670	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	9098	usd
	BLNC	Accreted Interest On Note Receivable AccretedInterestOnNoteReceivable	3308	usd
	BLNC	Equity Method Investment Summarized Financial Information Net Loss EquityMethodInvestmentSummarizedFinancialInformationNetLoss	46030	usd
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	6644	usd
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-231183	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-45000	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	22500	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	7690	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	87096	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	115561	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	60000	usd
	BLNC	Increase Decrease In Accumulated Income Losses Of Unconsolidated Investees In Excess Of Investment IncreaseDecreaseInAccumulatedIncomeLossesOfUnconsolidatedInvesteesInExcessOfInvestment	1226	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52911	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	211	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-52911	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	211	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	235311	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	227558	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	182400	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	227769	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52911	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	182400	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5157560	usd
CY2023Q2	BLNC	Working Capital Deficit WorkingCapitalDeficit	-3859520	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	2000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	2000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zjzymXTvOtHk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_866_z54nTxgpQFa9">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to stock-based compensation, depreciable lives of fixed assets and deferred tax assets. Actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1000000	shares
CY2022Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1000000	usd
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.00
CY2023Q2	us-gaap	Investment Owned Balance Shares InvestmentOwnedBalanceShares	66432	shares
CY2023Q2	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	155452	usd
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.34
	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	6644	usd
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 share for 8 share reverse stock split
CY2023Q2	us-gaap	Investments Investments	0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zfkUTcFFSmH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86E_zoS8FhHFMt15">Concentration of Credit Risk</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and marketable securities. As of June 30, 2023, and December 31, 2022, the carrying value of marketable securities was $<span id="xdx_90A_eus-gaap--MarketableSecurities_iI_pp0p0_c20230630_zG4wrWNR21F6" title="Marketable securities">155,452</span> and $<span id="xdx_901_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231_zWuL30tH423b" title="Marketable securities">148,808</span>, respectively. The securities are included in the Investment at Fair Value – Related Party on the consolidated balance sheets, which consist of common shares held in one (1) investment which currently is trading on the Over-the-Counter Bulletin Board (OTCBB).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Marketable Securities MarketableSecurities	155452	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	148808	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11316	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11316	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11316	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2394	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	48	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11316	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	BLNC	Notes Receivable Unamortized Allowance Current Percentage NotesReceivableUnamortizedAllowanceCurrentPercentage	1	pure
CY2023Q2	BLNC	Notes Receivable Unamortized Allowance Current NotesReceivableUnamortizedAllowanceCurrent	141000	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	500000	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	500000	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	14175	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	19845	usd
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	485825	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	480155	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	106850	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	106850	usd
CY2023Q2	BLNC	Due To Related Party Current DueToRelatedPartyCurrent	173192	usd
CY2022Q4	BLNC	Due To Related Party Current DueToRelatedPartyCurrent	173192	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	500000	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	500000	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	500000	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	500000	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	14175	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	19845	usd
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	485825	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	480155	usd

Files In Submission

Name	View Source	Status
0001493152-23-027864-index-headers.html	Edgar Link	pending
0001493152-23-027864-index.html	Edgar Link	pending
0001493152-23-027864.txt	Edgar Link	pending
0001493152-23-027864-xbrl.zip	Edgar Link	pending
blnc-20230630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
blnc-20230630_def.xml	Edgar Link	unprocessable
blnc-20230630_lab.xml	Edgar Link	unprocessable
blnc-20230630_cal.xml	Edgar Link	unprocessable
blnc-20230630_pre.xml	Edgar Link	unprocessable
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BLNC
Balance Labs, Inc. Stock $blnc

2023 Q3 Form 10-Q Financial Statement

#000149315223027864 Filed on August 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BLNC Balance Labs, Inc. Stock $blnc

2023 Q3 Form 10-Q Financial Statement

#000149315223027864 Filed on August 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BLNC
Balance Labs, Inc. Stock $blnc